Journal
JOURNAL OF PATHOLOGY
Volume 243, Issue 1, Pages 65-77Publisher
WILEY
DOI: 10.1002/path.4928
Keywords
pancreatic cancer; pancreatitis; acinar-to-ductal metaplasia; glycogen synthase kinase-3 beta; KRas; S6 K
Funding
- NCI Pancreatic Cancer SPORE [CA102701]
- National Natural Science Foundation of China [81472601]
- NCI [CA200572]
Ask authors/readers for more resources
Acinar-to-ductal metaplasia (ADM) is a reversible epithelial transdifferentiation process that occurs in the pancreas in response to acute inflammation. ADM can rapidly progress towards pre-malignant pancreatic intraepithelial neoplasia (PanIN) lesions in the presence of mutant KRas and ultimately pancreatic adenocarcinoma (PDAC). In the present work, we elucidate the role and related mechanism of glycogen synthase kinase-3beta (GSK-3 beta) in ADM development using in vitro 3D cultures and genetically engineered mouse models. We show that GSK-3 beta promotes TGF-beta-induced ADM in 3D cultured primary acinar cells, whereas deletion of GSK-3 beta attenuates caerulein-induced ADM formation and PanIN progression in KrasG12D transgenic mice. Furthermore, we demonstrate that GSK-3 beta ablation influences ADM formation and PanIN progression by suppressing oncogenic KRas-driven cell proliferation. Mechanistically, we show that GSK-3 beta regulates proliferation by increasing the activation of S6 kinase. Taken together, these results indicate that GSK-3 beta participates in early pancreatitis-induced ADM and thus could be a target for the treatment of chronic pancreatitis and the prevention of PDAC progression. Copyright (C) 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available